Priority Toxicology Laboratories, LLC

Priority Toxicology Laboratories, LLC was paid $3.59M by Medicaid between Apr 2018 and Oct 2024, across 44 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 64% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Georgia

Rank by total paid#13 of 66

Median peer was paid$178K

This provider vs. median20×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	2,100	$81K
2019	17,114	$1.76M
2020	7,458	$908K
2021	7,926	$539K
2022	9,859	$292K
2023	86	$4K
2024incomplete	257	$2K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	64%	14,513	8,778	$2.28M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	26%	17,939	9,841	$927K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	7.4%	4,159	1,881	$265K
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	2.4%	2,932	1,018	$87K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	166	134	$15K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	2,773	983	$10K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	161	58	$5K
80299		<1%	47	44	$722.90
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	80	38	$263.18
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	71	38	$26.32
87641		<1%	71	38	$26.32
80345		0%	48	45	$0.00

32 more codes

87640		0%	72	$0.00
80359		0%	65	$0.00
80368		0%	47	$0.00
80352		0%	48	$0.00
80358		0%	67	$0.00
80371		0%	47	$0.00
80333		0%	45	$0.00
80349		0%	44	$0.00
80357		0%	44	$0.00
80353		0%	65	$0.00
80321		0%	48	$0.00
80364		0%	68	$0.00
80325		0%	69	$0.00
80338		0%	44	$0.00
87653		0%	71	$0.00
80373		0%	67	$0.00
80360		0%	66	$0.00
80356		0%	65	$0.00
80354		0%	67	$0.00
80361		0%	67	$0.00
83992		0%	45	$0.00
87481		0%	71	$0.00
80365		0%	67	$0.00
80372		0%	45	$0.00
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	0%	71	$0.00
80323		0%	45	$0.00
80348		0%	68	$0.00
80347		0%	69	$0.00
80366		0%	47	$0.00
80342		0%	44	$0.00
80370		0%	45	$0.00
80355		0%	47	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialWILLIS, JEREMY (OWNER)